have determined the construct and criterion validity of the British Isles Lupus Assessment Group 2004 index (BILAG-2004), a revision of the Classic BILAG index for disease activity in systemic ...
GlobalData on MSN16d
Merck KGaA’s lupus drug fails in SLE cohort of Phase II triallupus drug enpatoran failed to meet the primary endpoint of British Isles Lupus Assessment Group (BILAG)-Based Composite ...
The 321-subject trial is comparing the anti-CD40L antibody to placebo on top of standard care in SLE patients, with the primary endpoint response on the BILAG 2004-based Composite Lupus Assessment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback